177 related articles for article (PubMed ID: 11213098)
1. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.
Ramsay ME; Andrews N; Kaczmarski EB; Miller E
Lancet; 2001 Jan; 357(9251):195-6. PubMed ID: 11213098
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
4. Estimating the burden of serogroup C meningococcal disease in England and Wales.
Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
[TBL] [Abstract][Full Text] [Related]
5. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
6. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
7. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.
Miller E; Salisbury D; Ramsay M
Vaccine; 2001 Oct; 20 Suppl 1():S58-67. PubMed ID: 11587814
[TBL] [Abstract][Full Text] [Related]
8. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
Larrauri A; Cano R; García M; Mateo Sd
Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
[TBL] [Abstract][Full Text] [Related]
9. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
10. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
Trotter CL; Edmunds WJ; Ramsay ME; Miller E
Hum Vaccin; 2006; 2(2):68-73. PubMed ID: 17012888
[TBL] [Abstract][Full Text] [Related]
11. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.
Knuf M; Kieninger-Baum D; Habermehl P; Muttonen P; Maurer H; Vink P; Poolman J; Boutriau D
Vaccine; 2010 Jan; 28(3):744-53. PubMed ID: 19887137
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacy clinics. Medication of the month. Meningitec].
Lepage P
Rev Med Liege; 2001 Feb; 56(2):124-5. PubMed ID: 11294047
[TBL] [Abstract][Full Text] [Related]
13. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
15. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
Trotter CL; Ramsay ME
FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
[TBL] [Abstract][Full Text] [Related]
16. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
17. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of meningococcal serogroup C vaccine programmes.
Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
[TBL] [Abstract][Full Text] [Related]
19. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
20. The new meningococcal conjugate vaccine. A profile of its safety, efficacy, and indications for use.
Pichichero ME
Postgrad Med; 2006; 119(1):47-54, 64. PubMed ID: 16913647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
